Titre :

Factors associated with covid-19-related death in people with rheumatic diseases: results from the covid-19 global rheumatology alliance physician-reported registry

Auteur(s) :

Strangfeld, Anja [Auteur]
Schafer, Martin [Auteur]
Gianfrancesco, Milena A. [Auteur]
Lawson-Tovey, Saskia [Auteur]
Liew, Jean W. [Auteur]
Ljung, Lotta [Auteur]
Mateus, Elsa F. [Auteur]
Richez, Christophe [Auteur]
Santos, Maria J. [Auteur]
Schmajuk, Gabriela [Auteur]
Scire, Carlo A. [Auteur]
Sirotich, Emily [Auteur]
Sparks, Jeffrey A. [Auteur]
Sufka, Paul [Auteur]
Thomas, Thierry [Auteur]
Université de Lyon, Saint-Etienne, F-42023, France
Trupin, Laura [Auteur]
Wallace, Zachary S. [Auteur]
Al-Adely, Sarah [Auteur]
Bachiller-Corral, Javier [Auteur]
Bhana, Suleman [Auteur]
Cacoub, Patrice [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Carmona, Loreto [Auteur]
Costello, Ruth [Auteur]
Costello, Wendy [Auteur]
Gossec, Laure [Auteur]
Grainger, Rebecca [Auteur]
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hasseli, Rebecca [Auteur]
Hausmann, Jonathan S. [Auteur]
Hyrich, Kimme L. [Auteur]
Izadi, Zara [Auteur]
Jacobsohn, Lindsay [Auteur]
Katz, Patricia [Auteur]
Kearsley-Fleet, Lianne [Auteur]
Robinson, Philip C. [Auteur]
Yazdany, Jinoos [Auteur]
Machado, Pedro M. [Auteur]

Titre de la revue :

Annals of the Rheumatic Diseases

Nom court de la revue :

Ann Rheum Dis

Numéro :

80

Pagination :

930–942

Date de publication :

2021-06-17

ISSN :

1468-2060

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

To determine factors associated with COVID-19-related death in people with rheumatic diseases. Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July ...
Lire la suite >To determine factors associated with COVID-19-related death in people with rheumatic diseases. Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category. Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death. Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:44:48Z
2024-01-08T14:07:21Z